Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination.
immunotherapy
programmed cell death 1 receptor
radiotherapy
tumor microenvironment
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
accepted:
17
09
2022
entrez:
17
10
2022
pubmed:
18
10
2022
medline:
20
10
2022
Statut:
ppublish
Résumé
Immunotherapy is currently part of the standard of care for patients with advanced-stage non-small cell lung cancer (NSCLC). However, many patients do not respond to this treatment, therefore combination strategies are being explored to increase clinical benefit. The PEMBRO-RT trial combined the therapeutic programmed cell death 1 (PD-1) antibody pembrolizumab with stereotactic body radiation therapy (SBRT) to increase the overall response rate and study the effects on the tumor microenvironment (TME). Here, immune infiltrates in the TME of patients included in the PEMBRO-RT trial were investigated. Tumor biopsies of patients treated with pembrolizumab alone or combined with SBRT (a biopsy of the non-irradiated site) at baseline and during treatment were stained with multiplex immunofluorescence for CD3, CD8, CD20, CD103 and FoxP3 for lymphocytes, pan-cytokeratin for tumors, and HLA-ABC expression was determined. The total number of lymphocytes increased significantly after 6 weeks of treatment in the anti-PD-1 group (fold change: 1.87, 95% CI: 1.06 to 3.29) and the anti-PD-1+SBRT group (fold change: 2.29, 95% CI: 1.46 to 3.60). The combination of SBRT and anti-PD-1 induced a 4.87-fold increase (95% CI: 2.45 to 9.68) in CD103 This explorative study shows that that lymphocyte infiltration in general, instead of the infiltration of a specific lymphocyte subset, is associated with response to therapy in patients with NSCLC.Furthermore, anti-PD-1+SBRT combination therapy induces an immunological abscopal effect in the TME represented by a superior infiltration of cytotoxic T cells as compared with anti-PD-1 monotherapy.
Sections du résumé
BACKGROUND
Immunotherapy is currently part of the standard of care for patients with advanced-stage non-small cell lung cancer (NSCLC). However, many patients do not respond to this treatment, therefore combination strategies are being explored to increase clinical benefit. The PEMBRO-RT trial combined the therapeutic programmed cell death 1 (PD-1) antibody pembrolizumab with stereotactic body radiation therapy (SBRT) to increase the overall response rate and study the effects on the tumor microenvironment (TME).
METHODS
Here, immune infiltrates in the TME of patients included in the PEMBRO-RT trial were investigated. Tumor biopsies of patients treated with pembrolizumab alone or combined with SBRT (a biopsy of the non-irradiated site) at baseline and during treatment were stained with multiplex immunofluorescence for CD3, CD8, CD20, CD103 and FoxP3 for lymphocytes, pan-cytokeratin for tumors, and HLA-ABC expression was determined.
RESULTS
The total number of lymphocytes increased significantly after 6 weeks of treatment in the anti-PD-1 group (fold change: 1.87, 95% CI: 1.06 to 3.29) and the anti-PD-1+SBRT group (fold change: 2.29, 95% CI: 1.46 to 3.60). The combination of SBRT and anti-PD-1 induced a 4.87-fold increase (95% CI: 2.45 to 9.68) in CD103
CONCLUSION
This explorative study shows that that lymphocyte infiltration in general, instead of the infiltration of a specific lymphocyte subset, is associated with response to therapy in patients with NSCLC.Furthermore, anti-PD-1+SBRT combination therapy induces an immunological abscopal effect in the TME represented by a superior infiltration of cytotoxic T cells as compared with anti-PD-1 monotherapy.
Identifiants
pubmed: 36252995
pii: jitc-2022-005248
doi: 10.1136/jitc-2022-005248
pmc: PMC9577911
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Forkhead Transcription Factors
0
Keratins
68238-35-7
pembrolizumab
DPT0O3T46P
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: WSMET reports grants from AstraZeneca, MSD and Sanofi.
Références
Front Immunol. 2018 Jul 26;9:1741
pubmed: 30093907
J Thorac Oncol. 2017 Jul;12(7):1085-1097
pubmed: 28478231
J Int Med Res. 2019 Aug;47(8):3818-3830
pubmed: 31187666
Kardiochir Torakochirurgia Pol. 2014 Mar;11(1):34-9
pubmed: 26336391
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Cancer Sci. 2003 Nov;94(11):1003-9
pubmed: 14611679
Cancer. 2020 Jan 15;126(2):260-270
pubmed: 31691957
Cancer Res. 2014 Oct 1;74(19):5458-68
pubmed: 25274032
Expert Rev Respir Med. 2020 Apr;14(4):367-383
pubmed: 31917616
Radiother Oncol. 2016 Aug;120(2):185-94
pubmed: 27495145
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Am J Clin Oncol. 2015 Feb;38(1):90-7
pubmed: 25616204
Cancer Discov. 2017 Dec;7(12):1420-1435
pubmed: 29025772
Trends Cancer. 2017 Nov;3(11):797-808
pubmed: 29120755
Cancer. 2008 Sep 15;113(6):1387-95
pubmed: 18671239
Clin Cancer Res. 2016 Apr 15;22(8):1865-74
pubmed: 27084740
Nat Commun. 2017 Oct 26;8(1):1136
pubmed: 29070816
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Front Immunol. 2018 Nov 16;9:2654
pubmed: 30505306
N Engl J Med. 2017 Jun 1;376(22):2109-2121
pubmed: 28445112
Front Immunol. 2019 Feb 01;9:3101
pubmed: 30774636
J Immunother Cancer. 2021 Apr;9(4):
pubmed: 33827905
Eur J Cancer. 2019 Jan;106:144-159
pubmed: 30528799
Clin Lung Cancer. 2018 Jul;19(4):e399-e404
pubmed: 29519614
Immunity. 2020 Jan 14;52(1):17-35
pubmed: 31940268
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Nat Immunol. 2016 Dec;17(12):1467-1478
pubmed: 27776108
Biomed J. 2017 Aug;40(4):200-211
pubmed: 28918908
J Immunol. 2018 Jan 1;200(1):347-354
pubmed: 29141863
Ther Adv Med Oncol. 2018 Apr 06;10:1758835918762094
pubmed: 29662546
Nature. 2017 Aug 24;548(7668):466-470
pubmed: 28759889
Immunotherapy. 2019 Dec;11(17):1445-1461
pubmed: 31826745
Clin Cancer Res. 2008 Aug 15;14(16):5220-7
pubmed: 18698040
Front Immunol. 2017 Mar 08;8:231
pubmed: 28337197
J Clin Invest. 2014 Feb;124(2):687-95
pubmed: 24382348
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
J Immunol. 2015 Apr 1;194(7):3475-86
pubmed: 25725111
Cancer Cell. 2013 Nov 11;24(5):589-602
pubmed: 24209604
Nat Methods. 2019 Jul;16(7):565-566
pubmed: 31217592
Clin Cancer Res. 2019 Aug 1;25(15):4592-4602
pubmed: 30824587
Nat Med. 2007 Sep;13(9):1050-9
pubmed: 17704786
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
Transl Lung Cancer Res. 2019 Feb;8(1):107-115
pubmed: 30788240
JAMA Oncol. 2019 Sep 01;5(9):1276-1282
pubmed: 31294749
Trends Immunol. 2018 Aug;39(8):644-655
pubmed: 30001871
J Clin Oncol. 2019 Oct 1;37(28):2518-2527
pubmed: 31154919
J Clin Invest. 2011 Jun;121(6):2254-63
pubmed: 21537083
Oncotarget. 2017 Dec 19;9(3):4120-4133
pubmed: 29423109
J Exp Med. 2006 May 15;203(5):1259-71
pubmed: 16636135
Cell Rep Med. 2020 Oct 20;1(7):100127
pubmed: 33205076
Semin Cancer Biol. 2022 Sep;84:89-102
pubmed: 33631295